>
Switch to:

Allergy Therapeutics Cash-to-Debt

: 3.61 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Allergy Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2021 was 3.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Allergy Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.

The historical rank and industry rank for Allergy Therapeutics's Cash-to-Debt or its related term are showing as below:

OTCPK:AGYTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 3.61   Max: No Debt
Current: 3.61

0.01
No Debt

During the past 13 years, Allergy Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 3.61.

OTCPK:AGYTF's Cash-to-Debt is ranked higher than
66% of the 1049 Companies
in the Drug Manufacturers industry.

( Industry Median: 1.10 vs. OTCPK:AGYTF: 3.61 )

Allergy Therapeutics Cash-to-Debt Historical Data

The historical data trend for Allergy Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.65 5.08 11.26 3.04 3.61

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.26 3.62 3.04 4.03 3.61

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Cash-to-Debt falls into.



Allergy Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Allergy Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2021 is calculated as:

Allergy Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Allergy Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)